5,050 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Encore Global Management LP

Encore Global Management LP purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 5,050 shares of the biopharmaceutical company's stock, valued at approximately $3,149,000. Regeneron Pharmaceuticals comprises 3.1% of Encore Global Management LP's holdings, making the stock its 12th largest position.

Other large investors also recently modified their holdings of the company. WPG Advisers LLC increased its holdings in Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 25 shares during the last quarter. Western Wealth Management LLC bought a new position in Regeneron Pharmaceuticals in the first quarter worth approximately $26,000. SHP Wealth Management purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth $26,000. Titan Wealth CI Ltd purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth $29,000. Finally, Kemnay Advisory Services Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $31,000. Institutional investors own 83.31% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Benchmark upgraded Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating and set a $185.00 price target for the company in a research report on Tuesday, July 7th. Wall Street Zen raised Regeneron Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 15th. JPMorgan Chase & Co. cut their price objective on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an "overweight" rating for the company in a research note on Monday, May 18th. Leerink Partners increased their target price on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a "market perform" rating in a report on Monday, August 17th. Finally, Wells Fargo & Company raised their target price on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an "equal weight" rating in a research note on Friday, July 31st. Sixteen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $801.70.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). Approval was supported by the Phase 3 OPTIMA trial, which showed a 90% or greater reduction in new lesions at 56 weeks. As the first approved treatment demonstrating this benefit in FOP, Pasatru could expand Regeneron’s rare-disease portfolio and create a new revenue stream. Regeneron to challenge Ipsen as FDA clears bone disease drug
• Positive Sentiment: Regeneron is also pursuing growth in obesity treatment. An update on its Phase 2 olatorepatide study has drawn investor attention because the program could give the company exposure to the large and rapidly expanding obesity-drug market, although clinical and commercial risks remain. Regeneron’s Olatorepatide Trial Signals a Bid for Obesity Market Upside
• Neutral Sentiment: Multiple investor-law-firm notices announced a securities class action and a September 14, 2026 lead-plaintiff deadline. The claims relate to alleged disclosures about the Phase 3 Fianlimab-Libtayo melanoma trial; the notices themselves do not represent a new regulatory or operating development. Regeneron Investors Class Action Notice
• Negative Sentiment: The underlying litigation alleges that Regeneron misled investors about the viability and prospects of the Fianlimab-Libtayo trial, whose disappointing results reportedly caused a sharp share-price decline and an approximately $11 billion reduction in market value. Continued lawsuit announcements add reputational, legal-cost and potential financial-liability risks. Pomerantz Regeneron Investor Alert

Insider Activity

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the company's stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director owned 17,303 shares of the company's stock, valued at $11,249,545.45. This represents a 1.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the company's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 1,400 shares of company stock valued at $1,090,030. 6.97% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $834.04 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $847.00. The business has a 50 day simple moving average of $697.09 and a two-hundred day simple moving average of $716.73. The stock has a market capitalization of $85.87 billion, a PE ratio of 20.61, a P/E/G ratio of 1.41 and a beta of 0.22.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. During the same quarter last year, the business earned $12.81 earnings per share. Regeneron Pharmaceuticals's quarterly revenue was up 16.7% compared to the same quarter last year. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Tuesday, August 18th. Regeneron Pharmaceuticals's payout ratio is 9.29%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source